Expression of Syndecan-1 in Chronic Liver Diseases: Correlation With Hepatic Fibrosis.
Heparan sulfate proteoglycans
immunohistochemistry
liver fibrosis
syndecan-1
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
05
10
2020
revised:
29
10
2020
accepted:
30
10
2020
entrez:
6
1
2021
pubmed:
7
1
2021
medline:
22
6
2021
Statut:
ppublish
Résumé
The mechanisms underlying the contribution of the heparan sulfate proteoglycan syndecan-1 to liver tissue injury and to crucial biological processes, such as fibrogenesis, remain to be elucidated. Therefore, we investigated the immunohistochemical expression of syndecan-1 in chronic liver diseases (CLDs) and its probable role in hepatic fibrosis. Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections of biopsy material obtained from 128 patients diagnosed with CLDs. The correlation between syndecan-1 expression and the stage of fibrosis was investigated. According to the severity of fibrosis, cases were categorized into three groups: early fibrosis; intermediate fibrosis; advanced fibrosis. Syndecan-1 expression was significantly enhanced in advanced fibrosis compared to early (p<0.012) and intermediate (p<0.003) fibrosis. In CLDs, syndecan-1 immunohisto-chemical overexpression was found to be positively correlated with the severity of fibrosis, suggesting its probable role in hepatic fibrogenesis.
Sections du résumé
BACKGROUND/AIM
OBJECTIVE
The mechanisms underlying the contribution of the heparan sulfate proteoglycan syndecan-1 to liver tissue injury and to crucial biological processes, such as fibrogenesis, remain to be elucidated. Therefore, we investigated the immunohistochemical expression of syndecan-1 in chronic liver diseases (CLDs) and its probable role in hepatic fibrosis.
MATERIALS AND METHODS
METHODS
Immunohistochemistry was performed on formalin-fixed, paraffin-embedded tissue sections of biopsy material obtained from 128 patients diagnosed with CLDs. The correlation between syndecan-1 expression and the stage of fibrosis was investigated.
RESULTS
RESULTS
According to the severity of fibrosis, cases were categorized into three groups: early fibrosis; intermediate fibrosis; advanced fibrosis. Syndecan-1 expression was significantly enhanced in advanced fibrosis compared to early (p<0.012) and intermediate (p<0.003) fibrosis.
CONCLUSION
CONCLUSIONS
In CLDs, syndecan-1 immunohisto-chemical overexpression was found to be positively correlated with the severity of fibrosis, suggesting its probable role in hepatic fibrogenesis.
Identifiants
pubmed: 33402482
pii: 35/1/333
doi: 10.21873/invivo.12264
pmc: PMC7880772
doi:
Substances chimiques
Membrane Glycoproteins
0
SDC1 protein, human
0
Syndecan-1
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
333-339Informations de copyright
Copyright© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Liver Int. 2009 Feb;29(2):208-12
pubmed: 18694404
Hepatology. 2005 Jun;41(6):1313-21
pubmed: 15915461
Hypertension. 2010 Feb;55(2):233-5
pubmed: 20048190
J Hepatol. 1995 Jun;22(6):696-9
pubmed: 7560864
Cardiol Res Pract. 2019 Nov 11;2019:4750580
pubmed: 31815014
J Hepatol. 2015 Oct;63(4):1023-37
pubmed: 26116792
Cell Tissue Res. 2016 Sep;365(3):539-52
pubmed: 27411689
Biochem Soc Trans. 2006 Jun;34(Pt 3):442-5
pubmed: 16709182
PLoS One. 2012;7(10):e48091
pubmed: 23144729
JCI Insight. 2019 Aug 8;5:
pubmed: 31393853
Mol Med Rep. 2019 Jul;20(1):368-374
pubmed: 31115505
J Biol Chem. 2003 Oct 17;278(42):41003-12
pubmed: 12867431
J Histochem Cytochem. 2010 May;58(5):429-41
pubmed: 20124094
Matrix Biol. 2018 Aug;68-69:474-489
pubmed: 29454902
Hepatology. 1995 Apr;21(4):950-8
pubmed: 7705805
J Clin Invest. 2009 Nov;119(11):3236-45
pubmed: 19805913
Pathol Oncol Res. 2020 Apr;26(2):813-819
pubmed: 30826971
Clin Liver Dis (Hoboken). 2016 Oct 27;8(4):94-99
pubmed: 31041072
Ann Hepatol. 2009 Oct-Dec;8(4):283-91
pubmed: 20009126
Hepatology. 2017 Nov;66(5):1601-1615
pubmed: 28543100
J BUON. 2019 May-Jun;24(3):1106-1112
pubmed: 31424668
Cardiovasc Res. 2007 May 1;74(2):184-95
pubmed: 17109837
Annu Rev Biochem. 1999;68:729-77
pubmed: 10872465
J Biol Chem. 2006 Apr 28;281(17):11506-14
pubmed: 16492675
Circulation. 2007 Jan 30;115(4):475-82
pubmed: 17242279
Adv Wound Care (New Rochelle). 2015 Apr 1;4(4):235-249
pubmed: 25945286
Hypertension. 2010 Feb;55(2):249-56
pubmed: 20048198
World J Gastroenterol. 2016 Jan 7;22(1):379-93
pubmed: 26755884
Clin Sci (Lond). 2007 Mar;112(5):265-80
pubmed: 17261089
Annu Rev Pathol. 2011;6:425-56
pubmed: 21073339
Semin Liver Dis. 2007 Nov;27(4):413-26
pubmed: 17979077
Matrix Biol. 2012 Jan;31(1):3-16
pubmed: 22033227
Prog Mol Biol Transl Sci. 2010;93:213-33
pubmed: 20807647
FEBS J. 2017 Jan;284(1):27-41
pubmed: 27790852
Annu Rev Cell Dev Biol. 2010;26:89-114
pubmed: 20565253
J Biol Chem. 2009 Feb 6;284(6):3537-45
pubmed: 19073610
World J Gastroenterol. 2014 Jun 21;20(23):7260-76
pubmed: 24966597
J Virol. 2013 Jun;87(12):6866-75
pubmed: 23576506
Scand J Gastroenterol. 2012 Dec;47(12):1488-93
pubmed: 23137022
Gastroenterology. 2004 Jun;126(7):1795-808
pubmed: 15188175
Cell Microbiol. 2017 May;19(5):
pubmed: 27930836
Matrix Biol. 2015 Mar;42:11-55
pubmed: 25701227
Scand J Clin Lab Invest. 2008;68(4):260-9
pubmed: 18609066
J Clin Invest. 2007 Mar;117(3):539-48
pubmed: 17332881
FEBS J. 2019 Aug;286(15):2994-3007
pubmed: 30932318
Cell Tissue Res. 2010 Jan;339(1):31-46
pubmed: 19597846
Front Immunol. 2020 Feb 18;11:227
pubmed: 32133006
FEBS J. 2010 Oct;277(19):3876-89
pubmed: 20840585